An orally disintegrating tablet is provided, prepared by tabletting fine granules exhibiting controlled release of lansoprazole, and an additive that is capable of suppressing the destruction of fine granules during tabletting and can regulate the release of lansoprazole over an extended period of time, can maintain a therapeutically effective concentration over time and exhibits excellent destruction property in the oral cavity. An oral disintegrating tablet containing (i) fine granules demonstrating the controlled release of a pharmaceutically active ingredient that contains fine granules containing a pharmaceutically active ingredient and a coating layer containing a methacrylic acid / methyl acrylate / methyl methacrylate copolymer, where fine granules containing a pharmaceutically active ingredient, coated with more than 80 and not more than 300 wt.% copolymer, and (ii) fine granules demonstrating controlled release of the pharmaceutically active ingredient one containing a pharmaceutically active ingredient and a coating layer containing (a) an ethyl acrylate / methyl methacrylate copolymer； and (b) one or more kinds of polymers selected from the group consisting of a methacrylic acid / ethyl acrylate copolymer, hypromellose phthalate, carboxymethyl ethyl cellulose, polyvinyl acetate acetate phthalate, acetate and cellulose acetate phthalate, where the fine granules (i) and fine granules (ii) have an average particle size of not more than 500 μm, and the pharmaceutically active ingredient is Lance oprazole, or its optically active form, or its salt.Предложена разрушающаяся во рту таблетка, полученная таблетированием тонких гранул, демонстрирующих регулируемое высвобождение лансопразола, и добавка, которая способна подавлять разрушение тонких гранул во время таблетирования и может регулировать высвобождение лансопразола в течение продолжительного времени, может поддерживать терапевтически эффективную концентрацию в течение продолжительного времени и демонстриру
